New drug combo aims to unleash immune system against stubborn myeloma
NCT ID NCT06622005
First seen Apr 22, 2026 · Last updated May 22, 2026 · Updated 2 times
Summary
This early-phase trial tests whether adding an experimental drug called SX-682 to standard cancer drugs is safe for people with multiple myeloma that has come back or not responded to prior therapy. SX-682 works by blocking signals that suppress the immune system, potentially helping the body's own cells kill myeloma cells. About 15 participants will receive the combination to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.